Table of Content

1 Key Insights

2 Executive Summary of STS with lung metastases

3 STS with lung metastases Market Overview at a Glance
3.1 Market Share (%) Distribution of STS with lung metastases in 2017
3.2 Market Share (%) Distribution of STS with lung metastases in 2030

4 Disease Background and Overview: STS with lung metastases
4.1 Introduction
4.2 General symptoms of lung metastases
4.3 Prognostic factors
4.3.1 Histology
4.3.2 Disease-free interval (DFI)
4.3.3 Completeness of resection
4.3.4 Response to chemotherapy
4.4 Staging System
4.5 Diagnosis of Soft-Tissue Sarcomas with Lung Metastases

5 Case Reports
5.1 A multidisciplinary approach to giant soft tissue sarcoma of the chest wall: A case report
5.2 Pneumothorax as an adverse event in patients with lung metastases of soft tissue sarcoma under Eribulin treatment
5.3 Lung metastases of primary alveolar soft-part sarcoma occurring 20 years after initial treatment

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Epidemiology Methodology
6.3 Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM
6.1 Total Incident Cases of STS with lung metastases in the 7MM

7 United States Epidemiology
7.1 Assumptions and Rationale
7.2 Total Incident cases of Soft tissue sarcoma (STS) in the United States
7.3 Total incident cases of STS with lung metastases in the United States
7.4 Gender-specific incident cases of STS with lung metastases in the United States
7.5 Subtype-specific incident cases of STS with lung metastases in the United States

8 EU5 Epidemiology
8.1 Assumptions and Rationale
8.2 Germany Epidemiology
8.2.1 Total incident cases of Soft tissue sarcoma (STS) in Germany
8.2.2 Total incident cases of STS with lung metastases in Germany
8.2.3 Gender-specific incident cases of STS with lung metastases in Germany
8.2.4 Subtype-specific incident cases of STS with lung metastases in Germany
8.3 France Epidemiology
8.3.1 Total incident cases of Soft tissue sarcoma (STS) in France
8.3.2 Total incident cases of STS with lung metastases in France
8.3.3 Gender-specific incident cases of STS with lung metastases in France
8.3.4 Subtype-specific incident cases of STS with lung metastases (%) in France
8.4 Italy Epidemiology
8.4.1 Total incident cases of Soft tissue sarcoma (STS) in Italy
8.4.2 Total incident cases of STS with lung metastases in Italy
8.4.3 Gender-specific incident cases of STS with lung metastases in Italy
8.4.4 Subtype-specific incident cases of STS with lung metastases in Italy
8.5 Spain Epidemiology
8.5.1 Total incident cases of Soft tissue sarcoma (STS) in Spain
8.5.2 Total incident cases of STS with lung metastases in Spain
8.5.3 Gender-specific incident cases of STS with lung metastases in Spain
8.5.4 Subtype-specific incident cases of STS with lung metastases (%) in Spain
8.6 United Kingdom Epidemiology
8.6.1 Total incident cases of Soft tissue sarcoma (STS) in the United Kingdom
8.6.2 Total incident cases of STS with lung metastases in the UK
8.6.3 Gender-specific incident cases of STS with lung metastases in the UK
8.6.4 Subtype-specific incident cases of STS with lung metastases in the UK

9 Japan Epidemiology
9.1 Assumptions and Rationale
9.1.1 Total incident cases of Soft tissue sarcoma (STS) in Japan
9.1.2 Total incident cases of STS with lung metastases in Japan
9.1.3 Gender-specific incident cases of STS with lung metastases in Japan
9.1.4 Subtype-specific incident cases of STS with lung metastases (%) in Japan

10 Current Treatment and Medical Practices
10.1 Surgical Technique and Management
10.2 Adjunctive therapies
10.3 Treatment Algorithm

11 Unmet needs

12 Emerging Drugs
12.1 Annamycin: Moleculin
12.1.1 Product Description
12.1.2 Other Developmental Activities
12.1.3 Clinical Development
12.1.4 Product Profile

13 Patient Journey

14 STS with lung metastases: 7MM Analysis
14.1 Key Findings
14.2 Market Methodology
14.3 Market Size of STS with lung metastases in the 7MM
14.4 Market Size of STS with lung metastases by Therapies in the 7MM

15 7MM Market Outlook

16 United States
16.1 United States Market Size
16.1.1 Total market size of STS with lung metastases in the United States
16.1.2 Market Size of STS with lung metastases by Therapies in the US

17 EU-5 Countries
17.1 Germany Market Size
17.1.1 Total Market size of STS with lung metastases in Germany
17.1.2 Market Size of STS with lung metastases by therapies in Germany
17.2 France Market Size
17.2.1 Total Market size of STS with lung metastases in France
17.2.2 Market Size of STS with lung metastases by therapies in France
17.3 Italy Market Size
17.3.1 Total Market size of STS with lung metastases in Italy
17.3.2 Market Size of STS with lung metastases by therapies in Italy
17.4 Spain Market Size
17.4.1 Total Market size of STS with lung metastases in Spain
17.4.2 Market Size of STS with lung metastases by therapies in Spain
17.5 United Kingdom Market Size
17.5.1 Total Market size of STS with lung metastases in the United Kingdom
17.5.2 Market Size of STS with lung metastases by therapies in the UK

18 Japan
18.1 Japan Market Size
18.1.1 Total Market size of STS with lung metastases in Japan
18.1.2 Market Size of STS with lung metastases by therapies in Japan

19 Market Drivers

20 Market Barriers

21 SWOT Analysis

22 Recognized Establishments

23 Appendix
23.1 Bibliography
23.2 Report Methodology

24 DelveInsight Capabilities

25 Disclaimer

26 About DelveInsight



List of Figures


Figure 1: Diagnosis of Soft-Tissue Sarcoma with Lung Metastases
Figure 2: Imaging Tests for Soft-Tissue Sarcoma (STS)
Figure 3: Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM (2017–2030)
Figure 4: Total Incident Cases of STS with lung metastases in the 7MM (2017–2030)
Figure 5: Total Incident cases of STS (Soft tissue sarcoma) in the United States (2017–2030)
Figure 6: Total incident cases of STS with lung metastases in the United States (2017–2030)
Figure 7: Gender-specific incident cases of STS with lung metastases in the US (2017–2030)
Figure 8: Subtype-specific incident cases of STS with lung metastases in the US (2017–2030)
Figure 9: Total incident cases of Soft tissue sarcoma (STS) in Germany (2017–2030)
Figure 10: Total incident cases of STS with lung metastases in Germany (2017–2030)
Figure 11: Gender-specific incident cases of STS with lung metastases in Germany (2017–2030)
Figure 12: Subtype-specific incident cases of STS with lung metastases in Germany (2017–2030)
Figure 13: Total incident cases of Soft tissue sarcoma (STS) in France (2017–2030)
Figure 14: Total incident cases of STS with lung metastases in France (2017–2030)
Figure 15: Gender-specific incident cases of STS with lung metastases in France (2017–2030)
Figure 16: Subtype-specific incident cases of STS with lung metastases in France (2017–2030)
Figure 17: Total incident cases of Soft tissue sarcoma (STS) in Italy (2017–2030)
Figure 18: Total incident cases of STS with lung metastases in Italy (2017–2030)
Figure 19: Gender-specific incident cases of STS with lung metastases in Italy (2017–2030)
Figure 20: Subtype-specific incident cases of STS with lung metastases in Italy (2017–2030)
Figure 21: Total incident cases of Soft tissue sarcoma (STS) in Spain (2017–2030)
Figure 22: Total incident cases of STS with lung metastases in Spain (2017–2030)
Figure 23: Gender-specific incident cases of STS with lung metastases in Spain (2017–2030)
Figure 24: Subtype-specific incident cases of STS with lung metastases in Spain (2017–2030)
Figure 25: Total incident cases of Soft tissue sarcoma (STS) in the UK (2017–2030)
Figure 26: Total incident cases of STS with lung metastases in the UK (2017–2030)
Figure 27: Gender-specific incident cases of STS with lung metastases in the UK (2017–2030)
Figure 28: Subtype-specific incident cases of STS with lung metastases in the UK (2017–2030)
Figure 29: Total incident cases of Soft tissue sarcoma (STS) in Japan (2017–2030)
Figure 30: Total incident cases of STS with lung metastases in Japan (2017–2030)
Figure 31: Gender-specific incident cases of STS with lung metastases in Japan (2017–2030)
Figure 32: Subtype-specific incident cases of STS with lung metastases in Japan (2017–2030)
Figure 33: Management of Soft Tissue Sarcoma
Figure 34: Management of localized, clinically resectable STS
Figure 35: Management of advanced/metastatic, clinically resectable STS
Figure 36: Management of advanced/metastatic, clinically unresectable STS
Figure 37: Unmet needs
Figure 38: Market Size of STS with lung metastases in the 7MM in USD Million (2017–2030)
Figure 39: Market Size of STS with lung metastases by therapies in the 7MM, in USD Million (2017–2030)
Figure 40: Market Size of STS with lung metastases in the US, USD Millions (2017–2030)
Figure 41: Market Size of STS with lung metastases by therapies in the US, in USD Million (2017–2030)
Figure 42: Market Size of STS with lung metastases in Germany, USD Millions (2017–2030)
Figure 43: Market Size of STS with lung metastases by Therapies in Germany, in USD Million (2017–2030)
Figure 44: Market Size of STS with lung metastases in France, USD Millions (2017–2030)
Figure 45: Market Size of STS with lung metastases by Therapies in France, in USD Million (2017–2030)
Figure 46: Market Size of STS with lung metastases in Italy, USD Millions (2017–2030)
Figure 47: Market Size of STS with lung metastases by Therapies in Italy, in USD Million (2017–2030)
Figure 48: Market Size of STS with lung metastases in Spain, USD Millions (2017–2030)
Figure 49: Market Size of STS with lung metastases by Therapies in Spain, in USD Million (2017–2030)
Figure 50: Market Size of STS with lung metastases in the UK, USD Millions (2017–2030)
Figure 51: Market Size of STS with lung metastases by Therapies in the UK, in USD Million (2017–2030)
Figure 52: Market Size of STS with lung metastases in Japan, USD Millions (2017–2030)
Figure 53: Market Size of STS with lung metastases by Therapies in Japan, in USD Million (2017–2030)
Figure 54: Market Drivers
Figure 55: Market Barriers
Figure 56: SWOT Analysis of STS with lung metastases


List of Tables


Table 1: Summary of STS with lung metastases, Market, Epidemiology and Key Events (2017–2030)
Table 2: Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM (2017–2030)
Table 3: Total Incident Cases of STS with lung metastases in the 7MM (2017–2030)
Table 4: Total Incident cases of STS (Soft tissue sarcoma) in the United States (2017–2030)
Table 5: Total incident cases of STS with lung metastases in the United States (2017–2030)
Table 6: Gender-specific incident cases of STS with lung metastases in the US (2017–2030)
Table 7: Subtype-specific incident cases of STS with lung metastases in the US (2017–2030)
Table 8: Total incident cases of Soft tissue sarcoma (STS) in Germany (2017–2030)
Table 9: Total incident cases of STS with lung metastases in Germany (2017–2030)
Table 10: Gender-specific incident cases of STS with lung metastases in Germany (2017–2030)
Table 11: Subtype-specific incident cases of STS with lung metastases in Germany (2017–2030)
Table 12: Total incident cases of Soft tissue sarcoma (STS) in France (2017–2030)
Table 13: Total incident cases of STS with lung metastases in France (2017–2030)
Table 14: Gender-specific incident cases of STS with lung metastases in France (2017–2030)
Table 15: Subtype-specific incident cases of STS with lung metastases in France (2017–2030)
Table 16: Total incident cases of Soft tissue sarcoma (STS) in Italy (2017–2030)
Table 17: Total incident cases of STS with lung metastases in Italy (2017–2030)
Table 18: Gender-specific incident cases of STS with lung metastases in Italy (2017–2030)
Table 19: Subtype-specific incident cases of STS with lung metastases in Italy (2017–2030)
Table 20: Total incident cases of Soft tissue sarcoma (STS) in Spain (2017–2030)
Table 21: Total incident cases of STS with lung metastases in Spain (2017–2030)
Table 22: Gender-specific incident cases of STS with lung metastases in Spain (2017–2030)
Table 23: Subtype-specific incident cases of STS with lung metastases in Spain (2017–2030)
Table 24: Total incident cases of Soft tissue sarcoma (STS) in the UK (2017–2030)
Table 25: Total incident cases of STS with lung metastases in the UK (2017–2030)
Table 26: Gender-specific incident cases of STS with lung metastases in the UK (2017–2030)
Table 27: Subtype-specific incident cases of STS with lung metastases in the UK (2017–2030)
Table 28: Total incident cases of Soft tissue sarcoma (STS) in Japan (2017–2030)
Table 29: Total incident cases of STS with lung metastases in Japan (2017–2030)
Table 30: Gender-specific incident cases of STS with lung metastases in Japan (2017–2030)
Table 31: Subtype-specific incident cases of STS with lung metastases in Japan (2017–2030)
Table 32: Annamycin, Clinical Trial Description, 2020
Table 33: Market Size of STS with lung metastases in the 7MM in USD Million (2017–2030)
Table 34: Market Size of STS with lung metastases by therapies in the 7MM, in USD Million (2017 2030)
Table 35: The US Market Size of STS with lung metastases in USD Million (2017–2030)
Table 36: Market Size of STS with lung metastases by therapies in the US, in USD Million (2017–2030)
Table 37: Germany Market Size of STS with lung metastases in USD Million (2017–2030)
Table 38: Market Size of STS with lung metastases by therapies in Germany, in USD Million (2017–2030)
Table 39: France Market Size of STS with lung metastases in USD Million (2017–2030)
Table 40: Market Size of STS with lung metastases by therapies in France, in USD Million (2017–2030)
Table 41: Italy Market Size of STS with lung metastases in USD Million (2017–2030)
Table 42: Market Size of STS with lung metastases by therapies in Italy, in USD Million (2017–2030)
Table 43: Spain Market Size of STS with lung metastases in USD Million (2017–2030)
Table 44: Market Size of STS with lung metastases by therapies in Spain, in USD Million (2017–2030)
Table 45: The UK Market Size of STS with lung metastases in USD Million (2017–2030)
Table 46: Market Size of STS with lung metastases by therapies in the UK, in USD Million (2017–2030)
Table 47: Japan Market Size of STS with lung metastases in USD Million (2017–2030)
Table 48: Market Size of STS with lung metastases by therapies in Japan, in USD Million (2017–2030)